Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin Glargine 300 U/ML (GLA-300) from insulin Glargine 100 U/ML (GLA-100) in real-world US treatment settings Read more about Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin Glargine 300 U/ML (GLA-300) from insulin Glargine 100 U/ML (GLA-100) in real-world US treatment settings
Modelling subcutaneous absorption of U100 and U300 insulin GLARGINE in type 1 diabetes Read more about Modelling subcutaneous absorption of U100 and U300 insulin GLARGINE in type 1 diabetes
Cost-effectiveness of insulin GLARGINE 300 Units/ML (GLA-300) VS Insulin DEGLUDEC 100 Units/ML (IDEG) in T2D Read more about Cost-effectiveness of insulin GLARGINE 300 Units/ML (GLA-300) VS Insulin DEGLUDEC 100 Units/ML (IDEG) in T2D
Achievement of HbA1c targets in the diabetes unmet need with basal insulin Evaluation (DUNE) real-world study Read more about Achievement of HbA1c targets in the diabetes unmet need with basal insulin Evaluation (DUNE) real-world study
Onset 1: efficacy and safety of mealtime fast‑acting insulin aspart versus insulin aspart after 52 weeks Read more about Onset 1: efficacy and safety of mealtime fast‑acting insulin aspart versus insulin aspart after 52 weeks
Lower glucose variability and risk for hypoglycaemia on insulin Glargine 300 U/mL versus insulin Glargine 100 U/mL, evaluated by the low blood glucose index in randomized phase lll clinical crials Read more about Lower glucose variability and risk for hypoglycaemia on insulin Glargine 300 U/mL versus insulin Glargine 100 U/mL, evaluated by the low blood glucose index in randomized phase lll clinical crials
Longer acting basal insulin analogues ‘Toujeo’ and ‘Tresiba’ reduce treatment side effects; a therapeutic advance in selected patients Read more about Longer acting basal insulin analogues ‘Toujeo’ and ‘Tresiba’ reduce treatment side effects; a therapeutic advance in selected patients
Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal–bolus therapy in patients with type 2 diabetes: DUAL VII trial Read more about Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal–bolus therapy in patients with type 2 diabetes: DUAL VII trial
Day-to-day variability of fasting self-measured blood glucose associates with risk of hypoglycaemia in adults with type 1 and type 2 diabetes Read more about Day-to-day variability of fasting self-measured blood glucose associates with risk of hypoglycaemia in adults with type 1 and type 2 diabetes
